OBJECTIVES:  Examine the health care utilization and costs incurred by patients diagnosed with lymphoma in the US Medicare population. METHODS:  Patients diagnosed with lymphoma (International Classification of Diseases, 9^th Revision, Clinical Modification diagnosis codes 200.4x, 200.7x, 202.0x, and 202.8x) were identified using 100% national Medicare data from 01JAN2009-31DEC2013. The first diagnosis date was designated as the index date, and patients were required to have continuous medical and pharmacy benefits 12 months pre- and post-index date. Study outcomes included demographic and clinical characteristics as well as health care costs and utilization for patients diagnosed with lymphoma. RESULTS:  A total of 299,349 lymphoma patients were included in the study. The mean age was 77 years. A majority of the patients were female (53.49%) and white (91.24%). Most patients resided in the South (36.62%), Midwest (25.27%), or Northeast (20.40%) US region. The mean Charlson Comorbidity Index score was 4.86 (standard deviation = 3.40). The most commonly diagnosed comorbid conditions included hypertension (78.13%), and diabetes mellitus (34.52%). Health care utilization was assessed, including the proportion of patients with inpatient (26.71%), emergency room (ER; 26.95%), physician office (94.02%), outpatient hospital (81.22%), skilled nursing facility (SNF; 7.11%), hospice (1.66%), home health agency (HHA; 14.60%), and durable medical equipment (DME; 41.11%) visits. Patients with lymphoma incurred higher mean health care costs, including inpatient ($6,729), ER ($279), physician office visit ($4,835), outpatient hospital ($9,371), SNF ($1,519), hospice ($352), HHA ($851), DME ($559), Part D pharmacy ($2,683), and total costs ($27,177). CONCLUSIONS: During a 12-month period, Medicare patients diagnosed with lymphoma incurred substantial health care utilization and costs.